A detailed history of Legal & General Group PLC transactions in Argenx Se stock. As of the latest transaction made, Legal & General Group PLC holds 110,272 shares of ARGX stock, worth $62.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
110,272
Previous 110,272 -0.0%
Holding current value
$62.2 Million
Previous $59.8 Million -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$434.22 - $551.9 $762,056 - $968,584
1,755 Added 1.62%
110,272 $59.8 Million
Q2 2024

Aug 14, 2024

BUY
$356.01 - $451.55 $9.56 Million - $12.1 Million
26,861 Added 32.9%
108,517 $46.7 Million
Q1 2024

May 14, 2024

BUY
$356.95 - $413.29 $1.2 Million - $1.39 Million
3,354 Added 4.28%
81,656 $32.1 Million
Q4 2023

Feb 15, 2024

BUY
$338.91 - $506.01 $4.72 Million - $7.04 Million
13,920 Added 21.62%
78,302 $29.8 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $1.11 Million - $1.64 Million
2,992 Added 4.87%
64,382 $31.7 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $3.68 Million - $4.32 Million
10,225 Added 19.98%
61,390 $23.9 Million
Q1 2023

May 15, 2023

BUY
$334.23 - $403.65 $594,260 - $717,689
1,778 Added 3.6%
51,165 $19.1 Million
Q4 2022

Feb 14, 2023

BUY
$342.17 - $402.31 $3.23 Million - $3.8 Million
9,453 Added 23.67%
49,387 $18.7 Million
Q3 2022

Nov 14, 2022

BUY
$343.2 - $395.75 $3.87 Million - $4.46 Million
11,278 Added 39.36%
39,934 $14.1 Million
Q2 2022

Aug 22, 2022

BUY
$269.58 - $378.88 $7.73 Million - $10.9 Million
28,656 New
28,656 $10.9 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.